Transcytosis vehicles and enchancers for drug delivery
AssigneeAndaris Limited
InventorsAndrew Derek Sutton, Asrar Bari Malik, Chinnaswamy Tiruppathi, Richard Alan Johnson
Life of this patent
Estimating the term…
Abstract
Transcytosis of a physiologically-active agent that exerts its action following passage across endothelia, epithelia or mesothelia containing the GP60 receptor is enhanced by formulation with or conjugation to a transcytosis enhancer or vehicle selected from albumin and fragments thereof, anti-GP60 antibody and fragments thereof, GP60 peptide fragments, and PDI (protein disulphide isomerase) and fragments thereof.
Claims15
A composition comprising, or conjugate of, a physiologically-active agent that exerts its action following passage across endothelia, epithelia or mesothelia containing the GP60 receptor, and a transcytosis enhancer or vehicle selected from albumin and fragments thereof, anti-GP60 antibody and fragments thereof, GP60 peptide fragments, and PDI (protein disulphide isomerase) and fragments thereof;
- wherein said composition or conjugate is a dry powder suitable for inhalation.
An inhaler device which comprises a composition comprising, or conjugate of, a physiologically-active agent that exerts its action following passage across endothelia, epithelia or mesothelia containing the GP60 receptor, and a transcytosis enhancer or vehicle selected from albumin and fragments thereof, anti-GP60 antibody and fragments thereof, GP60 peptide fragments, and PDI (protein disulphide isomerase) and fragments thereof;
- wherein said composition or conjugate is a dry powder suitable for inhalation.
Dependencies are inferred from the claim text.